Oregovomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CA125 |
| Clinical data | |
| Trade names | OvaRex |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | ca. 150 kg/mol |
  (what is this?) (verify) | |
Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.[1][2]
This drug was developed by AltaRex Corp.
References
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council - Oregovomab". American Medical Association. Archived from the original on 14 August 2003.
- ^ Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, et al. (February 2021). "Oregovomab: an investigational agent for the treatment of advanced ovarian cancer". Expert Opinion on Investigational Drugs. 30 (2): 103–110. doi:10.1080/13543784.2021.1868436. PMID 33423551.